In models of FGFR1-driven malignancies such as 8p11 myeloproliferative syndrome (EMS) and FGFR1-fusion positive leukemias, ponatinib effectively suppresses downstream signaling via pathways such as PLCγ, STAT5, ERK1/2, and AKT, leading to reduced proliferation and apoptosis induction in vitro and in vivo [153,154]. The gene discussed is FGFR1; the disease is leukemia.